tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Wilson CH et al. Prospective randomised trial of the use of Daclizumab in renal transplantation using kidneys from non heart beating donors. 2004 Ann. Transplant. pmid:15478912
Muraki Y et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. 2011 Oct-Dec Ann. Transplant. pmid:22210422
Boratyńska M et al. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. 2006 Ann. Transplant. pmid:17494290
Grochowiecki T et al. A retrospective study of steroid elimination in simultaneous pancreas and preemptive kidney transplant (Sppre-Ktx) recipients. 2006 Ann. Transplant. pmid:17494291
Rhu J et al. Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. 2017 Ann. Transplant. pmid:29180612
Mocchegiani F et al. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis. 2014 Ann. Transplant. pmid:25347718
Fox BD et al. Tacrolimus Levels Are Not Associated with Risk of Malignancy in Lung Transplant Recipients. 2017 Ann. Transplant. pmid:29133776
Rehman S et al. Effect of different tacrolimus levels on early outcomes after kidney transplantation. 2014 Ann. Transplant. pmid:24509826
Legris T et al. Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols. 2013 Ann. Transplant. pmid:24231646
Hakeam HA et al. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. 2008 Ann. Transplant. pmid:18566560
Girman P et al. The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. 2001 Ann. Transplant. pmid:11803619
Gijsen VM et al. Tacrolimus-induced nephrotoxicity and genetic variability: a review. 2012 Apr-Jun Ann. Transplant. pmid:22743729
Urbanowicz T et al. Induction therapy, tacrolimus plasma concentration, and duration if intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation. 2014 Ann. Transplant. pmid:25274118
Baron PW et al. Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression. 2017 Ann. Transplant. pmid:28533501
Furmańczyk A et al. Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation. 2009 Oct-Dec Ann. Transplant. pmid:20009155
Gerlach UA et al. Aspergillus spondylodiscitis after multivisceral transplantation. 2009 Oct-Dec Ann. Transplant. pmid:20009156
Malinowski M et al. Effect of tacrolimus dosing on glucose metabolism in an experimental rat model. 2010 Jul-Sep Ann. Transplant. pmid:20877268
Roan JN et al. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. 2013 Ann. Transplant. pmid:23792500
Tanaka T et al. Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. 2013 Ann. Transplant. pmid:23792533
El-Agroudy AE et al. Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications. 2008 Ann. Transplant. pmid:19034223
Miyata Y et al. Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. 2016 Ann. Transplant. pmid:27503662
Mizuno S et al. Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients. 2013 Ann. Transplant. pmid:23845965
Herden U et al. Early Initiation of Everolimus After Liver Transplantation: A Single-Center Experience. 2016 Ann. Transplant. pmid:26842532
Kuypers DR Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. 2008 Ann. Transplant. pmid:18806728
Grenda R et al. Evaluation of the genetic background of standard-immunosuppressant-related toxicity in a cohort of 200 paediatric renal allograft recipients--a retrospective study. 2009 Jul-Sep Ann. Transplant. pmid:19644155
Fukazawa K et al. Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation. 2011 Jul-Sep Ann. Transplant. pmid:21959523
Figurski MJ et al. Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. 2012 Jan-Mar Ann. Transplant. pmid:22466911
Acott P and Babel N BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? 2012 Jan-Mar Ann. Transplant. pmid:22466913
Ogura Y et al. Early Conversion From Twice-Daily Tacrolimus to Prolonged-Release Tacrolimus in Liver Transplantation: A Single-Center Experience. 2016 Ann. Transplant. pmid:27432248
Dedinská I et al. Waist circumference as an independent risk factor for NODAT. 2015 Ann. Transplant. pmid:25791039
Zahn A et al. Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis. 2013 Ann. Transplant. pmid:24088725
WÅ‚odarczyk Z et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. 2002 Ann. Transplant. pmid:12465429
Park S et al. Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study. 2018 Ann. Transplant. pmid:29891834
Rostaing L et al. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. 2014 Ann. Transplant. pmid:25017487
Jannot M et al. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. 2014 Ann. Transplant. pmid:24999809
Provenzani A et al. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. 2009 Jan-Mar Ann. Transplant. pmid:19289993
Urbanowicz T et al. Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation. 2014 Ann. Transplant. pmid:24949728
Fuchs U et al. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus. 2014 Ann. Transplant. pmid:24953848
Hošková L et al. Comparison of Cystatin C and NGAL in Early Diagnosis of Acute Kidney Injury After Heart Transplantation. 2016 Ann. Transplant. pmid:27226081
Wu P et al. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. 2011 Jan-Mar Ann. Transplant. pmid:21436775
Schnitzbauer AA et al. Delayed bottom-up and amended simple method of dosing with once-daily tacrolimus application to achieve stable trough levels in liver transplantation. 2015 Ann. Transplant. pmid:25553853
Mahalati K and Kahan BD Pharmacological surrogates of allograft outcome. 2000 Ann. Transplant. pmid:11217202
Garlicki M et al. Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation. 2006 Ann. Transplant. pmid:17025026
Van Laecke S et al. Effect of Magnesium Supplements on Insulin Secretion After Kidney Transplantation: A Randomized Controlled Trial. 2017 Ann. Transplant. pmid:28848225
Kitazawa F et al. Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. 2017 Ann. Transplant. pmid:28947731
Hirano Y et al. Prolonged Administration of Twice-Daily Bolus Intravenous Tacrolimus in the Early Phase After Lung Transplantation. 2017 Ann. Transplant. pmid:28798289
Illsinger S et al. Effect of tacrolimus on energy metabolism in human umbilical endothelial cells. 2011 Apr-Jun Ann. Transplant. pmid:21716189
Duvoux C et al. Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection. 2015 Ann. Transplant. pmid:25588713
Mijal J et al. Formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction. 2002 Ann. Transplant. pmid:12854345
Thölking G et al. Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation. 2016 Ann. Transplant. pmid:27003330